Marked effects of combined TPGS and PVA emulsifiers in the fabrication of etoposide-loaded PLGA-PEG nanoparticles: In vitro and in vivo evaluation

Saadati, Roonak; Dadashzadeh, Simin

doi:10.1016/j.ijpharm.2014.01.014

Cited by 50 publications

(29 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristic bands at 1464 and 1343 cm -1 are associated with the C-H bending. The stretching of C-C-O group appears at 1280 and 1100 cm are attributed to C-O-C group and C-H bond of the methyl group, respectively [32,[34][35][36][37] . The Figure 3c shows the PLGA-PEG spectrum.…”

Section: Resultsmentioning

confidence: 99%

Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin

et al. 2016

View full text Add to dashboard Cite

SbstractOxaliplatin was inserted into polymeric matrices aiming to study the interaction of this drug with these polymers and its capability to diffuse to the environment. Tested polymers were: (1) polyethylene glycol (PEG), (2) poly(lactic-co-glycolic acid) (PLGA), and (3) a copolymer of them (PLGA-PEG). The latter two were synthesized by us using polycondensation in bulk. Oxaliplatin was included in the matrices by the melt mixing process followed by casting. Fourier tran sform infrared spectroscopy (FTIR), proton nuclear magnetic resonance ( 1 H-NMR) and X-ray diffraction (DRX) studies of the polymers were performed proving the obtaining of the desired materials. In addition, the interaction between drug and matrices and the release profile of the oxaliplatin from these matrices were analyzed. Among them, PEG did not control the oxaliplatin release. In turn, PLGA and PLGA-PEG present drug release profiles quite similar. Oxaliplatin was completely released from PLGA and PLGA-PEG in 5 hours, by a relaxation mechanism. There was no evidence of oxaliplatin interaction with the different polymers. In addition, as the PEG improves the biocompatibility and biomasking, obtained results prove the obtaining of a drug release system, which allowed the total use of the drug improving the cancer treatment and even the welfare of the patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Barwicz et al have decreasing the aggregation state of the drug (Barwicz et al, 1992;Adams and Kwon, 2003). Currently, PLAG and PLGA-PEG are being used to improve the release rate of different classes of drugs from NPs systems intended for both parenteral (Allémann et al, 1998;Huh et al, 2003;Packhaeuser et al, 2004;Cheng et al, 2007;Saadati & Dadashzadeh, 2014;Teekamp et al, 2015) and oral administrations (Yoo & Park, 2001;Garinot et al, 2007;Fernandez-Carballido et al, 2008;Khalil et al, 2013;Yan et al, 2015). The ability of PLGA-PEG to enhance bioavailability of hydrophobic drugs, has been demonstrated for different classes of drugs.…”

Section: Discussionmentioning

confidence: 99%

Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats

et al. 2017

View full text Add to dashboard Cite

Amphotericin B (AMB) is used most commonly in severe systemic life-threatening fungal infections. There is currently an unmet need for an efficacious (AMB) formulation amenable to oral administration with better bioavailability and lower nephrotoxicity. Novel PEGylated polylactic-polyglycolic acid copolymer (PLGA-PEG) nanoparticles (NPs) formulations of AMB were therefore studied for their ability to kill Candida albicans (C. albicans). The antifungal activity of AMB formulations was assessed in C. albicans. Its bioavalability was investigated in nine groups of rats (n ¼ 6). Toxicity was examined by an in vitro blood hemolysis assay, and in vivo nephrotoxicity after single and multiple dosing for a week by blood urea nitrogen (BUN) and plasma creatinine (PCr) measurements. The MIC of AMB loaded to PLGA-PEG NPs against C. albicans was reduced two to threefold compared with free AMB. Novel oral AMB delivery loaded to PLGA-PEG NPs was markedly systemically available compared to Fungizone Õ in rats. The addition of 2% of GA to the AMB formulation significantly (p50.05) improved the bioavailability from 1.5 to 10.5% and the relative bioavailability was4790% that of Fungizone Õ . The novel AMB formulations showed minimal toxicity and better efficacy compared to Fungizone Õ . No nephrotoxicity in rats was detected after a week of multiple dosing of AMB NPs based on BUN and PCr, which remained at normal levels. An oral delivery system of AMB-loaded to PLGA-PEG NPs with better efficacy and minimal toxicity was formulated. The addition of glycyrrhizic acid (GA) to AMB NPs formulation resulted in a significant oral absorption and improved bioavailability in rats.

show abstract

“…1), and is most commonly used to stabilize emulsions caused by the formation of relatively small-sized particles with uniform size distribution. 34,35) PVA could reside at the PEG and hard fat interface and stabilize the PEG/ hard fat dispersion, i.e., the tablets using PEG and hard fat as the base formed the PEG/hard fat dispersion because of the stabilizing effects of PVA at the interface. PVA at the interface should play an important role in the significant increase observed in adhesiveness of the tablets using PEG and hard fat as the base because PVA could be present at the surface of the tablet.…”

Section: Discussionmentioning

confidence: 99%

Development of Polyethylene Glycol and Hard Fat-Based Mucoadhesive Tablets Containing Various Types of Polyvinyl Alcohols as Mucoadhesive Polymers for Buccal Application

Ikeuchi-Takahashi

Kobayashi

Onishi

2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Topical drug application has the advantage of avoiding systemic side effects. We attempted to develop a long-acting matrix-type tablet containing indomethacin (IM) with low physical stimulus and potent mucoadhesive force to treat pain caused by oral aphtha. A mixture of polyethylene glycol (PEG) and hard fat was used as the tablet base. Ethylcellulose was added to the base in an attempt to control drug release. Tablets with PEG as a base were also prepared for comparison. Polyvinyl alcohols (PVAs) with various degrees of saponification were added to increase the mucoadhesive force. From the optical microscopic observations, formulations using PEG and hard fat exhibit PEG/hard fat dispersions caused by the stabilizing effects of PVA. Although the tablets using PEG and hard fat showed sufficient adhesiveness and sustained drug release, those using PEG as the base did not. Drug release was controlled by the amount of hard fat and the saponification degree of PVA. The drug release rate was most increased in a tablet containing PVA with an intermediate degree of saponification, PEG and hard fat. From differential scanning calorimetry and powder X-ray diffraction, IM was considered to exist in the molecular phase. From the results of buccal administration of tablets to rats, highest tissue concentrations were observed in the tablet containing PVA with the intermediate degree of saponification using PEG and hard fat, and the plasma concentrations were sufficiently low in comparison.

show abstract

Marked effects of combined TPGS and PVA emulsifiers in the fabrication of etoposide-loaded PLGA-PEG nanoparticles: In vitro and in vivo evaluation

Cited by 50 publications

References 52 publications

Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin

Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin

Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats

Development of Polyethylene Glycol and Hard Fat-Based Mucoadhesive Tablets Containing Various Types of Polyvinyl Alcohols as Mucoadhesive Polymers for Buccal Application

Contact Info

Product

Resources

About